XML 32 R22.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENT	6 Months Ended
SUBSEQUENT EVENT	Jun. 30, 2011
SUBSEQUENT EVENT
SUBSEQUENT EVENT	NOTE P - SUBSEQUENT EVENTS On August 1, 2011, the Company entered into an agreement to acquire a 16% minority ownership in Aciex Therapeutics Inc. (“Aciex”), based in Westborough, MA, for $8,000,000 in cash. Aciex is an ophthalmic drug development company with a focus on developing novel therapeutics to treat ocular diseases. Aciex's pipeline consists of both clinical stage assets and pre-Investigational New Drug stage assets. In addition, the Company signed a global licensing agreement for a novel over-the-counter eye care product and manufacturing agreement for one of Aciex's lead prescription ophthalmic pipeline products.